Near Real-Time Monitoring

P95 developed this in the IMI ADVANCE project. We are now able to monitor near real-time benefits and risks of vaccines in the post-marketing stage. We were responsible for connecting to various data sources, data cleaning and quality assurance, data modelling and simulation, data visualisation, web application development and secure data access. More information: Dashboard on simulated data Dashboard with real data


P95 developed the Vaccine Effectiveness Misclassification (VEMC) application to perform calculations to quantify and adjust for the effect of exposure misclassification using novel statistical methods developed in the IMI ADVANCE project.

More information:


P95 developed this online calculation tool during the IMI ADVANCE project to allow researchers to calculate and adjust various interrelated indices (sensitivity, specificity, etc.) connected to epidemiologic research.


P95 developed the Electronic Study Support Application as a one-stop data upload and data quality assessment application for database custodians to use with their seasonal influenza data.

P95 has also been contracted to develop various web applications for top pharma clients and international partners (such as WHO, CEPI, etc.) on vaccine coverage, systematic literature review data and other topics.


Carmona, A., M. Latorre Tejerina, A. Martínez Sebastián, D. Dobreva, C. P. Jurca, S. Huerta Barberá, V. Bernat Montoya, M. Aristoy Zabaleta, A. Pineda Caplliure, B. Mansilla Roig, M. Navío Anaya, R. Tosca-Segura, M. Tortajada-Girbés, J. Díez-Domingo and A. Orrico-Sánchez (2022). “Risk Measurement of Perinatal and Neonatal Morbidity Characteristics and Applicability of GAIA Case Definitions: Results and Lessons Learnt of a Hospital-Based Prospective Cohort Study in the Valencia Region (2019-2020).” Int J Environ Res Public Health 19(12): 7132. 10.3390/ijerph19127132

Wang, W., S. Kothari, M. Baay, S. M. Garland, A. R. Giuliano, M. Nygard, C. Velicer, J. Tota, A. Sinha, J. Skufca, T. Verstraeten and K. Sundstrom (2022). “Real-world impact and effectiveness assessment of the quadrivalent HPV vaccine: a systematic review of study designs and data sources.” Expert Rev Vaccines 21(2): 227-240. 10.1080/14760584.2022.2008243

Chacon-Cruz, E., E. Meroc, S. A. Costa-Clemens, R. Clemens and T. Verstraeten (2022). “Economic Evaluation of Universal Varicella Vaccination in Mexico.” Pediatr Infect Dis J 41(5): 439-444. 10.1097/INF.0000000000003448

Bollaerts, K., M. A. Fletcher, J. A. Suaya, G. Hanquet, M. Baay and B. D. Gessner (2022). “Vaccine-Preventable Disease Incidence Based on Clinically, Radiologically, and Etiologically Confirmed Outcomes: Systematic Literature Review and Re-analysis of Pneumococcal Conjugate Vaccine Efficacy Trials.” Clin Infect Dis 74(8): 1362-1371. 10.1093/cid/ciab649

Willame, C., C. Dodd, L. van der Aa, G. Picelli, H. D. Emborg, J. Kahlert, R. Gini, C. Huerta, E. Martin-Merino, C. McGee, S. de Lusignan, G. Roberto, M. Villa, D. Weibel, L. Titievsky and M. Sturkenboom (2021). “Incidence Rates of Autoimmune Diseases in European Healthcare Databases: A Contribution of the ADVANCE Project.” Drug Saf 44(3): 383-395. 10.1007/s40264-020-01031-1

Sharan, A., S. Jahagirdar, A. L. Stuurman, V. Elango, M. Riera-Montes, N. Kumar Kashyap, N. Kumar Arora, M. Mathai, P. Mangtani, H. Devlieger, S. Anderson, B. Whitaker, H. L. Wong, C. L. Cutland and C. Guillard Maure (2022). “Operational lessons learned in conducting an international study on pharmacovigilance in pregnancy in resource-constrained settings: the WHO Global Vaccine Safety Multi-Country Collaboration project.” Vaccine X: 100160. 10.1016/j.jvacx.2022.100160

Click here for the full list (updated July 2022) 

© Copyright  2022   |   P95   |   ALL RIGHTS RESERVED